SYRS
Syros Pharmaceuticals Inc.
$0.01
+$0.00(+791.67%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
$16.10K
Volume
10.36K
52W Range
$0.00 - $3.40
Target Price
$1.00
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | $317.0K | $1.1M | $2.0M | $2.0M | $15.1M | $23.5M | $14.9M | $9.9M | ||
| Total Revenue | $317.0K | $1.1M | $2.1M | $2.0M | $15.1M | $23.5M | $14.9M | $9.9M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | $317.0K | $1.1M | $2.0M | $2.0M | $15.1M | $23.5M | $14.9M | $9.9M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $-48.3M | $-55.8M | $-66.3M | $79.7M | $97.4M | $122.9M | $141.2M | $136.4M | ||
| Research & Development | $37.8M | $41.9M | $50.2M | $58.2M | $76.1M | $99.9M | $111.9M | $108.2M | ||
| Research Expense | $37.8M | $41.9M | $50.2M | $58.2M | $76.1M | $99.9M | $111.9M | $108.2M | ||
| Selling, General & Administrative | $10.5M | $13.9M | $16.2M | $21.5M | $21.3M | $23.0M | $29.3M | $28.3M | ||
| General & Administrative Expenses | $10.5M | $13.9M | $16.2M | $21.5M | $21.3M | $23.0M | $29.3M | $28.3M | ||
| Salaries & Wages | $-4.2M | $-4.4M | $-6.6M | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-1.3M | $-1.5M | $-1.6M | $2.5M | $2.8M | $2.8M | $2.7M | $2.3M | ||
| Depreciation & Amortization | $-1.3M | $-1.5M | $-1.6M | $2.5M | $2.8M | $2.8M | $2.7M | $2.3M | ||
| Amortization | -- | -- | -- | $201.0K | $261.0K | $260.0K | $261.0K | -- | ||
| Other Operating Expenses | $-48.3M | $-55.8M | $-66.3M | $79.7M | $97.4M | $3.0M | $-9.5M | $3.1M | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-48.0M | $-54.7M | $-64.3M | $-77.7M | $-82.3M | $-99.4M | $-135.9M | $-129.0M | ||
| EBITDA | $-46.5M | $-52.6M | $-61.3M | $-73.6M | $-79.2M | $-79.6M | $-87.8M | $-157.2M | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $72.0K | $1.8M | $3.9M | $4.1M | $5.1M | ||
| Intinc | -- | -- | -- | $2.4M | $426.0K | $87.0K | $2.1M | $6.8M | ||
| Net Non-Operating Interest Income/Expense | -- | -- | -- | $2.3M | $-1.4M | $-3.8M | $-2.0M | $1.7M | ||
| Other Income/Expense | $-220.0K | $-676.0K | $-2.0M | $-100.0K | $375.0K | $-16.7M | $33.7M | $-39.8M | ||
| Other Special Charges | $220.0K | $676.0K | $2.0M | $2.3M | $-375.0K | $16.7M | $43.2M | $-37.3M | ||
| SPECIAL ITEMS | ||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | $2.5M | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | $-2.5M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | $500.0K | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-47.7M | $-54.0M | $-62.3M | $-75.4M | $-82.2M | $-82.7M | $-90.5M | $-159.4M | ||
| Pre-Tax Income | $-47.7M | $-54.0M | $-62.3M | $-75.4M | $-84.0M | $-86.6M | $-94.7M | $-164.6M | ||
| INCOME TAX | ||||||||||
| Tax Provision | $-2.0K | $-7.0K | $-24.0K | $28.0K | $4.0K | $1.0K | $3.0K | $1.0K | ||
| NET INCOME | ||||||||||
| Net Income | $-47.7M | $-54.0M | $-62.3M | $-75.4M | $-84.0M | $-86.6M | $-94.7M | $-164.6M | ||
| Net Income (Continuing Operations) | $-47.7M | $-54.0M | $-62.3M | $-75.4M | $-84.0M | $-86.6M | $-94.7M | $-164.6M | ||
| Net Income (Discontinued Operations) | $-47.7M | $-54.0M | $-62.3M | $-75.4M | $-84.0M | $-86.6M | $-94.7M | $-164.6M | ||
| Net Income (Common Stockholders) | $-51.4M | $-54.0M | $-62.3M | $-75.4M | $-84.0M | $-86.6M | $-94.7M | $-164.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-68.4M | -- | $-126.5M | ||
| TOTALS | ||||||||||
| Total Expenses | $-48.3M | $-55.8M | $-66.3M | $79.7M | $97.4M | $122.9M | $141.2M | $136.4M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $1.3M | $2.5M | $3.3M | $4.0M | $4.6M | $6.3M | $12.6M | $28.3M | ||
| Average Shares Outstanding (Diluted) | $1.2M | $2.5M | $3.3M | $4.0M | $4.6M | -- | $12.6M | $28.3M | ||
| Shares Outstanding | $2.3M | $3.2M | $3.3M | $4.3M | $6.2M | $6.2M | $20.3M | $26.5M | ||
| Basic EPS | -- | -- | -- | $-18.8 | $-18.2 | $-13.8 | $-7.49 | $-5.81 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-18.8 | $-18.2 | $-13.8 | $-7.49 | $-5.81 | ||
| Diluted EPS | $-40.5 | $-21.3 | $-19.1 | $-18.8 | $-18.2 | $-13.8 | $-7.49 | $-5.81 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-7.49 | $-5.81 | ||
| OTHER METRICS | ||||||||||
| Accrued Preferred Stock Dividends | $3.7M | -- | -- | -- | $375.0K | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | $100.0K | -- | -- | -- | -- | ||
| Other Gand A | $10.5M | $13.9M | $16.2M | $21.5M | $21.3M | $23.0M | $29.3M | $28.3M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | $500.0K | ||
| Otherunder Preferred Stock Dividend | $3.7M | -- | -- | -- | $375.0K | -- | -- | -- | ||
| Preferred Stock Dividends | $3.7M | -- | -- | -- | $375.0K | -- | -- | -- | ||
| Rent And Landing Fees | $10.5M | $13.9M | $16.2M | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | $2.5M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SYRS | $0.01 | +791.7% | 10.36K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Syros Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW